Hospital Británico de Buenos Aires - CABA
Desde el año 2000, el Centro de Oncología del Hospital Británico de Buenos Aires es un espacio que combina calidad asistencial en oncología con una visión centrada en el paciente y en la innovación a través de la investigación clínica. Nuestra misión y visión nos impulsa a la mejora continua participando en el desarrollo y aplicación de nuevos tratamientos para los pacientes con diagnóstico de cáncer en nuestro país.Perdriel 74, CABA, Buenos Aires
Select an option
I am a doctor
I am a sponsor
Specializations
Cáncer de mama
Cáncer de pulmón
Cáncer de próstata
Cáncer de vejiga
Cáncer de riñón
Cáncer
Tumores sólidos Cáncer
Enfermedad de Crohn
Bacteriemia por estafilococo aureus Bacteriemia
Leucemia
Colitis ulcerosa
Hipertensión pulmonar
Pan Tumor Cáncer
Hipertensión arterial pulmonar
Melanoma
Enfermedad de Huntington
Artroplastia Reemplazo de rodilla
Miocardiopatía
Nefropatía Enfermedad renal
Enfermedad renal crónica Anemia
Carcinoma hepatocelular Cáncer de hígado
Nefropatía
Colangitis biliar primaria
Our team
Medical staff
Astrid Rausch
Agustín Miguez
Maria Dolores Daneri
Belén Virasoro
Silvina Palmer
Karina Vera
Natalia Roldan
Micalea Conde
Anahí Martinez
María Acevedo
Anahi Martinez
Ernesto Korbenfeld
Luciana Bella Quero
Yamila Chichotky
Maximiliano Romero
Karina Alejandra Vera
Cintia Novas
Luis Colombato
Patricia Delgado
Hernán Trimarchi
Juan Andres de Paula
Nora Fernández
Javier Benavides
Patricia Delgado
Mariana Lopez
Hugo Armando Laborde
Macarena Saenz
Maria Victoria Dolores Mujica
Claudia M. Shanley
Valentina Russo
Open studies
Lung cancer
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy - DAREON ® -Lung-1 - Boehringer IngelheimSee more
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer - EVOKE-SCLC-04 - Gilead SciencesSee more
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations - Beamion LUNG-3 - Boehringer IngelheimSee more
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - ABBV-399 - AbbVieSee more
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - ABBV-399 - AbbVieSee more
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% - RELATIVITY1093 - Bristol-Myers SquibbSee more
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) - MK-2870-019 - Merck Sharp & Dohme LLCSee more
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) - MK 2870-007 - Merck Sharp & Dohme LLCSee more
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) - MK 2870-007 - Merck Sharp & Dohme LLCSee more
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer - Krascendo 2 - Hoffmann-La RocheSee more
Colorectal cancer
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait - CCHOWW - Hospital Alemão Oswaldo CruzSee more
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation - CodeBreaK 301 - AmgenSee more
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer - ROSETTA CRC-203 - Bristol-Myers SquibbSee more
Prostate cancer
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer - rechARge - CelgeneSee more
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. - MEVPRO-3 - PfizerSee more
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) - OMAHA-003 - Merck Sharp & Dohme LLCSee more
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) - OMAHA-003 - Merck Sharp & Dohme LLCSee more
Breast Cancer
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer - OVELIA - Tolmar Inc.See more
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer - EvoPAR-BR01 - AstraZenecaSee more
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) - MK-2870-012 - Merck Sharp & Dohme LLCSee more
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) - MK-6482-029 LITESPARK-029 - Merck Sharp & Dohme LLCSee more
Steatohepatitis
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) - ENLIGHTEN-Fibrosis - 89bio, Inc.See more
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.See more
Fatty liver/nash
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) - ENLIGHTEN-Fibrosis - 89bio, Inc.See more
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.See more
Endometrial Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) - TroFuse-033 - Merck Sharp & Dohme LLCSee more
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer - Fern-EC-01 - BioNTech SESee more
Glomerulonephritis
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB - ACTION3 - Dimerix Bioscience Pty LtdSee more
Ulcerative colitis
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis - SUNSCAPE-1 - SanofiSee more
Solid tumors
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors - BEHOLD-2 - GlaxoSmithKlineSee more
Crohn's disease
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease - STARSCAPE-1 - SanofiSee more
Leukemia
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Non-Hodgkin Lymphoma
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Head and neck cancer
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) - MCLA-158-CL02 - Merus N.V.See more
Bile Duct Cancer
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement - FOENIX-CCA4 - Taiho Oncology, Inc.See more
Alzheimer disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease - MINDSET 1 - Bristol-Myers SquibbSee more
Cholangitis
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis - ELFIDENCE - IpsenSee more
Epilepsies
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy - RISE 2 - Biohaven Therapeutics Ltd.See more
Cirrhosis
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.See more
